Spruce Biosciences

Spruce Biosciences is a company that develops and commercializes novel therapies for rare endocrine disorders and neurological conditions with significant unmet medical needs. The company has approximately 11 employees and is focused on advancing its lead product candidate, tildacerfont, for the treatment of classic congenital adrenal hyperplasia, polycystic ovary syndrome, and major depressive disorder.